SCHEMBL24915969

SCHEMBL24915969

Cc1ccc2c(c1)C(C(C)C)CCO2

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADRA2A P08913 1/20 0.48
ALDH1A1 P00352 1/20 0.40
GAA P10253 1/20 0.40
MAPT P10636 1/20 0.40
HSD17B10 Q99714 1/20 0.40
HTR2C P28335 2/20 0.39
HTR1A P08908 2/20 0.39
SLC6A2 P23975 1/20 0.39
HTR2B P41595 1/20 0.39
SIGMAR1 Q99720 1/20 0.39
KDM4C Q9H3R0 1/20 0.38
MAP3K14 Q99558 2/20 0.36
TRPV1 Q8NER1 1/20 0.35
PIK3CA P42336 1/20 0.35
PIK3CB P42338 1/20 0.35
PIK3CG P48736 1/20 0.35
CHRNB2 P17787 1/20 0.34
CHRNA4 P43681 1/20 0.34
KMT2A Q03164 2/20 0.33
MEN1 O00255 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24915657 1.00 ADRA2A (0.48) ADRA2AALDH1A1GAAMAPTHSD17B10
SCHEMBL12609031 0.82 GRM7 (0.38) ADRA2AALDH1A1GAAHTR2CMAP3K14
SCHEMBL16691509 0.82 PTGS1 (0.36) ADRA2AGAAMAPTMAP3K14TRPV1
SCHEMBL12169251 0.82 GRM7 (0.38) ADRA2AALDH1A1GAAHTR2CMAP3K14
SCHEMBL12609027 0.82 GRM7 (0.38) ADRA2AALDH1A1GAAHTR2CMAP3K14
SCHEMBL23841478 0.82 MAP3K14 (0.51) ADRA2AGAAMAPTHTR2CHTR1A
SCHEMBL24915971 0.81 KCNH2 (0.37) ADRA2AKDM4CMAP3K14PIK3CAPIK3CB
SCHEMBL24915656 0.81 KCNH2 (0.37) ADRA2AKDM4CMAP3K14PIK3CAPIK3CB
SCHEMBL24915967 0.80 ENPP2 (0.46) MAPTHTR1AHTR2BSIGMAR1PKM
SCHEMBL24915659 0.80 ENPP2 (0.46) MAPTHTR1AHTR2BSIGMAR1PKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023129564-A9 DEGRADERS OF GRK2 AND USES THEREOF CYGNAL THERAPEUTICS, INC. (US) 2024-02-08 WO disclosed
WO-2023129564-A1 DEGRADERS OF GRK2 AND USES THEREOF CYGNAL THERAPEUTICS, INC. (US) 2023-07-06 WO disclosed
US-20230026466-A1 WDR5 INHIBITORS AND MODULATORS VANDERBILT UNIVERSITY 2023-01-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230026466-A1 WDR5 INHIBITORS AND MODULATORS WDR5, WDR1, WDR3 ADRA2A 4703/4885ALDH1A1 3815/4885GAA 3980/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.